-
Mashup Score: 3Early Onset Colorectal Symposium - 2 month(s) ago
Registration for this course will close on Thursday, March 7th at noon to allow time to prepare registration roster sheets, and other details. We will re-open r
Source: www.southpiedmontahec.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Should We Integrate Immune-Related Adverse Events as Biomarkers in Clinical Practice? - 6 month(s) ago
Studies have suggested a relationship between the occurrence of irAEs and improved treatment outcomes with ICIs, suggesting their potential utility as biomarkers. Authors explore recent data and provide their perspective.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Thank you@ASCO for the wonderful opportunity to contribute to #ASCODailyNews. Big shoutout to Drs. Musselwhite & Hanson for their outstanding collaboration Should We Integrate Immune-Related Adverse Events as Biomarkers in Clinical Practice? #immunotherapy https://t.co/tby7yiNOZR
-
-
Mashup Score: 3Should We Integrate Immune-Related Adverse Events as Biomarkers in Clinical Practice? - 6 month(s) ago
Studies have suggested a relationship between the occurrence of irAEs and improved treatment outcomes with ICIs, suggesting their potential utility as biomarkers. Authors explore recent data and provide their perspective.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Thank you@ASCO for the wonderful opportunity to contribute to #ASCODailyNews. Big shoutout to Drs. Musselwhite & Hanson for their outstanding collaboration Should We Integrate Immune-Related Adverse Events as Biomarkers in Clinical Practice? #immunotherapy https://t.co/tby7yiNOZR
-
-
Mashup Score: 3JCO Precision Oncology Conversations: KRAS Variants, G12C, TMB, high PD-L1 Expression in Solid Tumors on Apple Podcasts - 1 year(s) ago
Show JCO Precision Oncology Conversations, Ep KRAS Variants, G12C, TMB, high PD-L1 Expression in Solid Tumors – Mar 15, 2023
Source: Apple PodcastsCategories: Hem/Oncs, Latest HeadlinesTweet-
Many thanks to @JCOPO_ASCO for hosting me to discuss our G12C landscape paper. Deeply enjoyed my conversation with great host @thenasheffect. More research to come in this area. @OncoAlert @ASCO @LevineCancer https://t.co/PR66MFmPQQ
-
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
AuthorsSebastian BauerDepartment of Medical Oncology and Sarcoma Center/West German Cancer Center, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany; Sebastian Bauer, Robin Lewis Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Raymond Zalcberg, Yoon-Koo Kang,…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Very honored to moderate the January #ASCOPlenarySeries session and be joined with amazing speakers @seppobauer @breelynwilkyMD @ChristianRolfo Will highlight the role of #ctDNA in predicting tx efficacy in #GIST #. @3 PM today. Abst: https://t.co/L3CGCPLK9k @OncoAlert #GI23 https://t.co/CS21GfS22e
-
-
Mashup Score: 3Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers - 2 year(s) ago
PURPOSE Promising single-agent activity from sotorasib and adagrasib in KRASG12C-mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of KRAS-variant prevalence, genomic alterations, and the relationship between KRAS and immuno-oncology biomarkers is lacking. MATERIALS AND METHODS Retrospective analysis of deidentified records from…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Very pleased to see our #KRAS #G12C paper in print @JCOPO_ASCO. Many 🙏thanks to @JCO_ASCO editorial team & the reviewers. @ASCO @OncoAlert #precisionmedicine #colorectalcancer #lungcancer @ASCO_pubs https://t.co/5YWaXiuz6O
-
-
Mashup Score: 2
The BRAFV600E mutation is associated with the hypermethylator phenotype CIMP (CpG island methylator phenotype), which can also lead to the microsatellite instability-high (MSI-H) phenotype through hypermethylation of the MLH1 gene promoter.
Source: ASCO Daily NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
Discussing treatment options for #Patients With MSI-H BRAFV600E-Mutated Metastatic #Colorectal #Cancer #ASCODailyNews @ASCO Such a great honor to do this with the amazing #CRC scientist Pro Andre! @OncoAlert https://t.co/UH3QNGZsHr
-
-
Mashup Score: 0ASCO Daily News: War in Ukraine: Treating Patients Under Fire - 2 year(s) ago
Host Dr. John Sweetenham, of the UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center, interviews Dr. Mariia Kukushkina, of the National Cancer Institute of Ukraine in Kyiv, on the heroic efforts of oncologists to treat patients with cancer during Russia’s invasion of Ukraine. From her home in Kyiv, Dr. Kukushkina recounts how “some cancer centers have been destroyed.”
Source: ascodaily.libsyn.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Fascinating interview by @JSweetenhamMD with Dr. Mariia Kukushkina, of the National Cancer Institute of Ukraine in Kyiv, on the heroic efforts of oncologists care for cancer patients during Russia’s invasion of Ukraine. #ASCODailyNews @ASCO https://t.co/Q9J5rH0TfS
-
-
Mashup Score: 2
Original Article from The New England Journal of Medicine — Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
@NEJM ➡️ full publication of CheckMate 648 #clinicaltrial nivolumab ➕chemotherapy as first-line treatment in #patients with advanced #esophageal squamous #cancer @OncoAlert https://t.co/quNlo2ABe2
-
-
Mashup Score: 0Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial - 2 year(s) ago
First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib, but clinical activity and a favourable safety profile were observed in patients with advanced hepatocellular carcinoma. Thus, nivolumab might be considered a therapeutic option for patients in whom tyrosine kinase inhibitors and antiangiogenic drugs are contraindicated or have substantial risks.
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@TheLancetOncol- CM459➡️Nivolumab vs. sorafenib in #HCC showed no significant difference in OS ⬇️ mOS was 16·4 months with nivolumab and 14·7 months with sorafenib. #medtwitter would you use Nivo as first line? @OncoAlert https://t.co/Xe401z9liu
-
Join us tomorrow @LevineCancer @AtriumHealth for an inspiring Early Onset Colorectal Symposium. #ColorectalCancer #ColonCancerAwareness Month https://t.co/u5d8ixw4yv